Don P. Buesching

A review of the health-related quality of life literature in bipolar disorder

This paper reviews the existing literature on health-related quality of life assessments conducted in bipolar disorder patients, and provides recommendations for the use of specific scales to measure health-related quality of life in this population. A comprehensive review of the literature revealed only a handful of studies in bipolar disorder that had incorporated quality of life assessments. While instruments from the medical outcomes study (MOS) were the most frequently used to measure health-related quality of life, a number of other instruments like the physchological general well being scale (PGWB), the streamlined longitudinal interview clinical evaluation from the longitudinal interval follow-up evaluation (SLICE/LIFE), the Euroqol, (EQ-5D), the Lehmans quality of life interview (QLI), and the quality of life in depression scale (QLDS) were also used. Only three studies out of ten reported the psychometric properties of the measures used. In the absence of a disease-targeted measure, a combination of the SF-36 and the PGWB is presently recommended as the battery of choice to assess the health-related quality of life of individuals with bipolar disorder. There is also the need to develop a disease-targeted health-related quality of life measure for bipolar disorder, which will obviate the use of a burdensome battery of generic quality of life instruments.

Quality of Life of Adolescent Males with Attention-Deficit Hyperactivity Disorder.

Most psychosocial research on attention-deficit/hyperactivity disorder (ADHD) has focused on deficits in school, family, or behavioral functioning without incorporating perceived quality of life (QoL) or the adolescents’ perspective. The Youth Quality of Life Instrument—Research Version (YQOL-R), was used to assess self-perceived QoL in a community sample of adolescents aged 11—18 years. Fifty-five adolescent males with a clinical diagnosis of ADHD were compared to a group of 107 adolescents with no chronic conditions (NCC) and a group of 52 adolescents with mobility impairments (MI). The adolescents with ADHD reported significantly lower perceived QoL scores, particularly in the Self and Relationship domains, than the NCC group. Their scores were similar to those from the group with MI, a group previously shown to have a substandard QoL. Interventions to improve self-esteem and social interactions might use QoL outcomes in evaluating effectiveness.

The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization

Non-randomized studies of treatment effects have come under criticism because of their failure to control for potential biases introduced by unobserved variables correlated with treatment selection and outcomes. This paper describes the basic concepts of sample selection models--a technique used widely in the economics evaluation literature for nearly two decades--and discusses the potential role of these models in outcomes research. In addition, it presents a case study of the application of the sample selection modelling approach to evaluation of the effects of antidepressant therapies on medical expenditures for physician services. This case study presents empirical comparisons of alternative model specifications and discusses practical issues in evaluation of sample selection models. We demonstrate that, in this particular case, sample selection models yield very different conclusions regarding treatment effects than traditional ordinary least squares regression.

Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States

PURPOSE This study assessed first-line chemotherapy treatment patterns over time and identified predictors of chemotherapy use and treatment selection among elderly patients with newly diagnosed Stage IIIB/IV non-small cell lung cancer (NSCLC) in the United States. METHODS Patients aged 65 years and older newly diagnosed with Stage IIIB/IV NSCLC between 1997 and 2002 were identified and followed through 2003 using the Surveillance, Epidemiology and End Results (SEER)-Medicare database to evaluate temporal trends in chemotherapy treatment. Multivariate logistic regression models were estimated to identify predictors of chemotherapy treatment and factors associated with use of cisplatin/carboplatin (platinum) and either a taxane or gemcitabine versus other treatments. RESULTS Chemotherapy use increased from approximately 28% of Stage IIIB/IV NSCLC patients diagnosed in 1997 to 36% of patients diagnosed in 2002. Doublet therapy was most commonly used as first-line therapy, received by 74% of chemotherapy-treated patients across all study years. Use of doublet therapy with platinum and either a taxane or gemcitabine also increased over time (with the largest increase for gemcitabine combinations from 0.3% in 1997 to 11.8% in 2002). Males were more likely than females to be treated with chemotherapy (odds ratios [95% CI]: 1.14 [1.06-1.22]), as were patients in the Northeast and South relative to patients in the West (1.24 [1.13-1.36] and 1.33 [1.20-1.47], respectively). CONCLUSION Use of first-line chemotherapy treatment among elderly Stage IIIB/IV NSCLC patients is low, but appears to be increasing, with potential regional and gender differences in treatment. These findings are likely to be of interest to clinicians and policymakers.

Bootstrap Analyses of Cost Effectiveness in Antidepressant Pharmacotherapy

SummaryIn this study, we describe ‘bootstrap’ methodology for placing statistical confidence limits around an incremental cost effectiveness ratio (ICER). This approach was applied to a retrospective study of annual charges for patients undergoing pharmacotherapy for depression.We used MarketScanSM(service mark) data from 1990 to 1992, which includes medical and pharmacy claims for a privately insured group of employed individuals and their families in the US. Our primary effectiveness measure was the proportion of patients who remained stable on their initial antidepressant medication for at least 6 consecutive months. Our primary cost measure was the total annual charge incurred by patients taking the selective serotonin reuptake inhibitor fluoxetine, a tricyclic antidepressant or a heterocyclic antidepressant.On average, fluoxetine pharmacotherapy tended to decrease annual charges by

Health economic evaluations of antidepressants: A review

US16.48 per patient for each percentage increase in depressed patients remaining stable on initial pharmacotherapy for 6 months, resulting in a negative ICER point-estimate. However, the upper ICER confidence limit is positive, which means that fluoxetine treatment may possibly increase annual per patient charges. With 95% confidence, any such increase was no more than

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysis

US130 per patient for each percentage increase in patients remaining stable on initial pharmacotherapy for at least 6 months.One advantage of using a bootstrap approach to ICER analysis is that it does not require restrictive distributional assumptions about cost and outcome measures. Bootstrapping also yields a dramatic graphical display of the variability in cost and effectiveness outcomes that result when a study is literally ‘redone’ hundreds of times. This graphic also displays the ICER confidence interval as a ‘wedge-shaped’ region on the cost-effectiveness plane. In fact, bootstrapping is easier to explain and appreciate than the elaborate calculations and approximations otherwise involved in ICER estimation.Our discussion addresses key technical questions, such as the role of logarithmic transformation in symmetrising highly skewed cost distributions. We hope that our discussion contributes to a dialogue, leading ultimately to a consensus on analysis of ICERs.

The impact on employment of an intervention to increase recognition of previously untreated anxiety among primary care physicians

In an era of constrained health care financing, clinicians are increasingly faced with considering the economic consequences in addition to the clinical outcomes associated with initiating a patient on antidepressant therapy. This has increased the demand for health economic studies comparing antidepressant use and associated health care expenditures in clinical practice. These health economics studies have used methods ranging from clinical trials to other types of analyses including prospective naturalistic trials or retrospective studies which may be less familiar to clinicians. Prospective and retrospective health economics studies performed in clinical practice complement the experience gained from clinical trials in assessing antidepressant use and economic outcomes in light of patient and provider behavior within the usual care environment of a complex health care system. Broadly considered, health economic studies of antidepressants have consistently found differences in clinical practice between the tricyclic antidepressants (TCAs) and the selective serotonin reuptake inhibitors (SSRIs) as well as among the SSRIs. These differences relate to the pattern and duration of antidepressant use as well as total direct health care expenditures. Future health economic research studies in clinical practice should focus on the economic consequences of long‐term antidepressant use as well as the impact of antidepressant use on indirect costs such as productivity and absenteeism. Depression and Anxiety 7:53–64, 1998.

Cardiovascular events and insulin therapy : A retrospective cohort analysis

AIMS To compare total costs and risk of hypoglycemia in patients with type 2 diabetes (T2D) initiated on NPH insulin versus glargine in a real-world setting. METHODS This study used claims data (10/2001 to 06/2005) from a privately insured U.S. population of adult T2D patients who were initiated on NPH or glargine following a 6-month insulin-free period. A sample of 1698 glargine-treated and 400 NPH-treated patients met the inclusion criteria. Total and diabetes-related costs (inflation-adjusted to 2006) were calculated for 6-month pre- and post-index periods and compared between 400 patient pairs matched by a propensity score method. RESULTS In the post-index 6-month period, glargine patients incurred higher diabetes-related drug costs than NPH patients (

Information Needs for Medication Coverage Decisions in a State Medicaid Program

785 versus